An interventional study of Exercise in Fibromyalgia (FM), sponsored by European University Miguel de Cervantes. Recruiting at 1 site in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-16.
Sponsored by European University Miguel de Cervantes · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 151 studies in Fibromyalgia with a site in Spain — 16 open to participants now, 21 under way, none of them phase 3. Fibromyalgia · Spain.
Among the 151 studies in Fibromyalgia with a site in Spain, this one is the 114th largest by planned enrollment of the 135 interventional ones that give a count, is one of 6 that started in 2026, is one of 113 with no phase, reaches primary completion later than 14 of the 20 other live ones, and was the 144th registered.
1,245 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.
Browse Fibromyalgia studies →16 of the 151 studies in Fibromyalgia with a site in Spain are open now. Recruiting first, the newest first:
Ionclinics & Deionic SL · Sites in Spain
Ages 18+
University of Valladolid · Sites in Spain
Ages 18+
Cardenal Herrera University · Sites in Spain
Ages 18–80
Parc de Salut Mar · Sites in Spain
Ages 18–70 · Women only
Universitat de Lleida · Sites in Spain
Ages 18–65
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 161 Fibromyalgia studies recruiting now, 51 (32%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
151 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 36 is below the median of 60 across 938 interventional studies indexed under Fibromyalgia.
Median enrollment 66 across the 135 interventional studies, 90 across the 15 observational. Of the 107 that completed or were terminated, 10 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 151 have an industry lead sponsor. The 10 most frequent:
European University Miguel de Cervantes is the lead sponsor of 16 studies on the registry; 9 are open to participants now.
European University Miguel de Cervantes has 1 study filed under Fibromyalgia — fewer than ten, so there is no comparison to draw.
5 of the studies in Fibromyalgia with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07424534University of Castilla-La ManchaPredictive Models on Psychosocial Profile, Fatigue and Sleep Quality | 2026-11-30 |
| NCT06948500Cardenal Herrera UniversityEffectiveness of an IVR-based Therapeutic Exercise Program With Altered Visual Feedback in Fibromyalgia Patients | 2026-12-01 |
| NCT07693998University of ValenciaPain Neuroscience Education for Chronic Pain | 2026-12-31 |
| NCT04084795Parc de Salut MarAugmentation of EMDR With tDCS in the Treatment of Fibromyalgia | 2026-12-31 |
| NCT05962437Fundació Sant Joan de DéuSelf-guided Acceptance and Commitment Therapy-based Digital Smartphone Application for Management of Fibromyalgia | 2027-03-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 151 studies in Fibromyalgia with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Fibromyalgia is a chronic syndrome characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and functional impairment, which significantly affects quality of life. Physical exercise is considered one of the most effective non-pharmacological interventions for the management of this condition; however, uncertainty remains regarding the most appropriate type, intensity, and frequency of exercise for different patient profiles. The aim of this study is to analyze the effects of a microdoses isokinetic exercise program on physical condition, perceived pain, inflammatory profile and quality of life in women diagnosed with fibromyalgia.
Physical exercise is one of the non-pharmacological treatments with the strongest evidence and effectiveness in the management of fibromyalgia, as it has been shown to improve muscle strength and, consequently, patients' quality of life. One of the main limitations in this population is low adherence to traditional exercise programs due to chronic pain. Microdoses exercise training emerges as an alternative approach, based on the principle of the minimum effective dose. To implement this intervention, the training program will be conducted using isokinetic exercise, which allows precise control of movement velocity and joint position to ensure safe conditions. Accordingly, the aim of the present study is to evaluate the effects of an isokinetic exercise microdosing program in women with fibromyalgia over an 8-week intervention period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An isokinetic exercise program of microdosing will be conducted over 8 weeks, with a frequency of three sessions per week, each lasting 20-25 minutes. Participants will also receive information on healthy lifestyle habits.
Other: Exercise
Participants assigned to the control group will continue with their usual treatment and will receive general recommendations for healthy lifestyle.
Participants assigned to the experimental group will perform the sessions under supervision. Each session will begin with a warm-up consisting of joint mobility exercises and 5 minutes of low-intensity cycling. This will be followed by the main exercise component, which will consist of one set of five repetitions of knee extension exercise. During the initial sessions, the exercise will be performed at 60°/s, with a gradual and controlled progression up to a maximum of eight repetitions. To finish, participants will complete 5 minutes of stretching and controlled breathing.
Peak torque
The change in the peak torque (in Nm) will be assessed in the concentric part of a knee extension exercise (1x5) at 60º/s using the Biodex System 4.
Time frame: Baseline, up to study completion (8 weeks); week 9
Peak torque
The change in the peak torque (in Nm) will be assessed in the eccentric part of a knee extension exercise (1x5) at 60º/s using the Biodex System 4.
Time frame: Baseline, up to study completion (8 weeks); week 9
Agonist-antagonist ratio
The change in the agonist-antagonist ratio (%) of the knee extension exercise will be assessed using the Biodex System 4.
Time frame: Baseline, up to study completion (8 weeks); week 9
Total work
The change in the total work (in J) of the knee extension exercise will be assessed using the Biodex System 4.
Time frame: Baseline, up to study completion (8 weeks); week 9.
Height
The change in the height will be assessed by centimeters (cm).
Time frame: Baseline, week 9
Muscle electrical activity (amplitude)
The MuscleLab system with electromyography will be used to measure muscle electrical activity in vastus lateralis (in microvolts) recording during exercise, following the standard recommendations for electrode placement and with signal normalization.
Time frame: Baseline, week 9
Muscle electrical activity (frequency)
The MuscleLab system with electromyography will be used to measure muscle electrical activity in vastus lateralis (in Hz) recording during exercise, following the standard recommendations for electrode placement and with signal normalization.
Time frame: Baseline, week 9
Muscle electrical activity (amplitude)
The MuscleLab system with electromyography will be used to measure muscle electrical activity in rectus femoris (in microvolts) recording during exercise, following the standard recommendations for electrode placement and with signal normalization.
Time frame: Baseline, week 9
Muscle electrical activity (frequency)
The MuscleLab system with electromyography will be used to measure muscle electrical activity in in rectus femoris bilateral (in Hz) recording during exercise, following the standard recommendations for electrode placement and with signal normalization.
Time frame: Baseline, week 9
Weight
The change in the weight will be assessed by kilograms (kg).
Time frame: Baseline, week 9
Body composition (Bioimpedance)
The change in body composition (%) will be assessed using the NUTRILAB bioimpedance device (AKERN Srl, Florence, Italy). Users will be instructed to remove all metal-containing objects and remain in a supine position on a couch during the measurements, with the legs in 45° abduction, the shoulders in 30° abduction relative to the center of the body and the hands in pronation. After cleaning the skin with alcohol, two adhesive electrodes (Biatrodes Akern Srl, Florence, Italy) will be placed on the surface of the right hand and two on the right foot. The measurement results will be given in different unit measures depending on the specific variable assessed.
Time frame: Baseline, week 9.
Muscle thickness
The change in the muscle thickness (in centimeters) of the vastus lateralis will be measured using a real-time B-mode ultrasound device with a linear transducer. A water-soluble, hypoallergenic transmission gel will be applied to the probe, to serve as a conductive interface between the probe and the participant's skin.
Time frame: Baseline, week 9.
Muscle thickness
The change in the muscle thickness (in centimeters) of the rectus femoris bilateral will be measured using a real-time B-mode ultrasound device with a linear transducer. A water-soluble, hypoallergenic transmission gel will be applied to the probe, to serve as a conductive interface between the probe and the participant's skin.
Time frame: Baseline, week 9.
Pain score
The change in the score of pain will be assessed through a Numeric Rating Scale (NRS), numbered from 0 "no pain at all" to 10 "worst pain imaginable."
Time frame: Baseline, up to study completion (8 weeks); week 9.
Pain location
The pain location will be assessed using a body chart. The participant will identify using a graphical representation of the body the location of the pain, without indicating its intensity.
Time frame: Baseline, up to study completion (8 weeks); week 9.
Quality of life: Short Form 36 Health Survey
The change in quality-of-life scores will be assessed using the Short Form 36 Health Survey (SF-36). This instrument consists of 36 items, organized into eight health domains, with a score ranging from 0 to 100.
Time frame: Baseline, week 9.
Quality of life: EuroQOL five dimensions questionnaire
The change in quality-of-life scores will be assessed using the EuroQOL five-dimensions questionnaire (EQ-5D). This instrument consists of five dimensions and a visual analogue scale (VAS).The response types involve a Likert scale (1-5 for dimensions), multiple-choice (selecting the level), and a rating scale (0-100 for VAS).
Time frame: Baseline, week 9.
Sleep quality
The change in sleep quality scores will be assessed using the Pittsburgh Sleep Quality Index (PSQI). This index consists of 19 self-rated items, which are grouped into seven component scores, ranging from 0 to 21.
Time frame: Baseline, week 9.
Physical activity levels
The levels of physical activity will be recorded using the International Physical Activity Questionnaire (score) a standardized tool that defines and measures physical activity based on frequency (days) and duration (minutes) over a week. It categorizes physical activity into vigorous-intensity, moderate-intensity, and walking, and also assesses time spent sitting.
Time frame: Baseline, week 9.
Heart rate variability
The change in heart rate variability (HRV) will be measured in milliseconds (ms) to assess autonomic nervous system function. Participants will use a Polar H10 heart rate monitor (Polar Electro Oy, Kempele, Finland) with the Elite HRV app for 15 minutes.
Time frame: Baseline, week 9.
Interleukin-6 (IL-6) levels
The change in the plasma concentration of interleukin-6 (mg/l and/or ng/ml) will be assessed. Venous blood samples will be collected. The plasma concentrations will be analyzed using an enzyme-linked immunosorbent assay (ELISA).
Time frame: Baseline, week 9.
Tumor necrosis factor-alpha (TNF-α) levels
The change in the plasma concentration of tumor necrosis factor-alpha (mg/l and/or ng/ml) will be assessed. Venous blood samples will be collected. The plasma concentrations will be analyzed using an enzyme-linked immunosorbent assay (ELISA).
Time frame: Baseline, week 9.
C-reactive protein (CRP) levels
The change in the plasma concentration of C-reactive protein (mg/l and/or ng/ml) will be assessed. Venous blood samples will be collected. The plasma concentrations will be analyzed using an enzyme-linked immunosorbent assay (ELISA).
Time frame: Baseline, week 9.
Cortisol
Cortisol The change in the plasma concentration of cortisol (mg/l and/or ng/ml) will be assessed. Venous blood samples will be collected. The plasma concentrations will be analyzed using an enzyme-linked immunosorbent assay (ELISA).
Time frame: Baseline, week 9.
Glucose
The change in the plasma concentration of glucose (mg/l and/or ng/ml) will be assessed. Venous blood samples will be collected. The plasma concentrations will be analyzed using an enzyme-linked immunosorbent assay (ELISA).
Time frame: Baseline, week 9.
Testosterone (total)
The change in the plasma concentration of total testosterone (mg/l and/or ng/ml) will be assessed. Venous blood samples will be collected. The plasma concentrations will be analyzed using an enzyme-linked immunosorbent assay (ELISA).
Time frame: Baseline, week 9.
Testosterone (free)
The change in the plasma concentration of free testosterone (mg/l and/or ng/ml) will be assessed. Venous blood samples will be collected. The plasma concentrations will be analyzed using an enzyme-linked immunosorbent assay (ELISA).
Time frame: Baseline, week 9.
Sex hormone-binding globulin
The change in the plasma concentration of sex hormone-blinding globulin (mg/l and/or ng/ml) will be assessed. Venous blood samples will be collected. The plasma concentrations will be analyzed using an enzyme-linked immunosorbent assay (ELISA).
Time frame: Baseline, week 9.
Dehydroepiandrosterone sulfate
The change in the plasma concentration of dehydroepiandrosterone sulfate (mg/l and/or ng/ml) will be assessed. Venous blood samples will be collected. The plasma concentrations will be analyzed using an enzyme-linked immunosorbent assay (ELISA).
Time frame: Baseline, week 9.
Fibromyalgia Impact Questionnaire
The change in the score of the fibromyalgia impact will be assessed using the fibromyalgia impact questionnaire (FIQ), a 10-item questionnaire that covers Physical Function, Work Status, and Symptoms. The total score ranges from 0 to 100, a higher score (closer to 100) indicates a greater impact of fibromyalgia, signifying higher functional disability, more severe symptoms, and a worse quality of life. Conversely, a lower score (closer to 0) indicates a better health status.
Time frame: Baseline, week 9.
Nutritional intake: Consume frequency
The change in the dietary intake (consume frequency) will be assessed with a Food Frequency Questionnaire (FFQ). This tool measures how often foods and food groups are consumed over a specific period, enabling the estimation of typical dietary patterns. The total days per week that a participant consumes a type of food will be recorded.
Time frame: Baseline, week 9.
Nutritional intake: 24-hour register
The change in the dietary intake will be assessed with a 24-hour dietary recall . This tool measures how often foods and food groups are consumed over a specific period, enabling the estimation of typical dietary patterns.
Time frame: Baseline, week 9.
Canadian Occupational Performance Measure
The change in the occupational performance score will we assessed using the Canadian Occupational Performance Measure (COPM). The participant will identify their priorities for activities in daily living. After priorities are identified, each is rated for current performance and satisfaction with current performance on a scale of 1 (not able to do it / not satisfied at all) to 10 (able to do it extremely well / extremely satisfied).
Time frame: Baseline, week 9.
Goal Attainment Scaling
The change in the goal achievement progress will be assessed using Goal Attainment Scaling, a standardized individualized outcome measure in which five measurable outcomes are specified for each goal. The total score will range from -2 to 2.
Time frame: Baseline, week 9.
Plan to share: No
Start is estimated for Apr 2026; primary completion for Jul 2026, 3 months later.
Of 439 non-industry interventional studies with no phase under Fibromyalgia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 31. This study's planned 3 months is below that.
Counting every sponsor, half of 452 studies reached it within 15 months; a quarter within 6 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
European University Miguel de Cervantes